A retrospective analysis of <scp>EBV‐DNA</scp> status with the prognosis of lymphoma

Qiu, Lihua; Si, Junqi; Kang, Junnan; Chen, Zehui; Nuermaimaiti, Rexidan; Qian, Zhengzi; Li, Lanfang; Zhou, Shiyong; You, M. James; Zhang, Huilai; Tian, Chen

doi:10.1111/jcmm.17543

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariate analysis further demonstrated that DNA4 had an independent effect on the prognosis of PTCL for OS. Consistent with previous studies by Song et al ( 2022 ), Shen et al ( 2022 ), and Qiu et al ( 2022 ), EBV DNA emerged as an effective prognostic marker. It appears that EBV DNA may be superior to EBER, possibly because EBER is a qualitative diagnostic index derived from tissue samples, whereas EBV DNA is a quantitative measurement analyzed from plasma samples.…”

Section: Discussionsupporting

confidence: 90%

“…DNA was extracted from plasma samples using the EBV PCR Fluorescence Quantitative Diagnostic Kit. Copy numbers were analyzed using a standard curve, with 500 copies/mL defined as the critical value based on previous studies (Kim et al 2021 ; Shen et al 2022 ; Zeng et al 2022 ; Qiu et al 2022 ). If EBV DNA was less than 500 copies/mL, it was recorded as 0.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma

Chen,

Zhou,

Cheng

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose To explore the prognostic and therapeutic role of Epstein-Barr Virus (EBV) on peripheral T-cell lymphoma (PTCL). Methods Totally 262 newly diagnosed PTCL patients who were hospitalized from January 2014 to December 2022 were retrospectively enrolled. Molecular analysis included 31 eligible patients. EBV-encoded RNA (EBER) presence in tumor tissue and EBV DNA levels in patients at baseline (DNA1) and after 4 cycles of chemotherapy (DNA4) were assessed. Results Our findings revealed that the EBER-positive cohort exhibited significant differences compared to counterparts in overall survival (OS, P = 0.047) and progression-free survival (PFS, P = 0.009). Both DNA1 and DNA4 were significantly associated with inferior OS. Multivariate analysis demonstrated that DNA4 independently affected PTCL prognosis for OS (hazard ratio = 5.1617; 95% confidence interval 1.1017–24.1831; P = 0.037). Treatment with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus azacytidine regimen showed a better OS compared to CHOP or CHOP plus etoposide for patients with partially positive EBER and EBER positive statuses (P = 0.192), although the improvement was not statistically significant. This study delineated the genetic paradigm of PTCL, comparing genetic differences by EBV status and found that EBER partially positive plus positive patients were more likely to have DNMT3A (P = 0.002), RHOAG17V (P = 0.023), and TET2 mutations (P = 0.032). Conclusion EBER, DNA1, and DNA4 emerged as sensitive markers for prognosis. CHOP plus azacytidine might present a preferable option for PTCL patients with DNA methylation due to EBV infection.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Methodsmentioning

confidence: 99%

Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma

Chen,

Zhou,

Cheng

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Etiological study of polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients and proposal of a diagnostic aid algorithm

ANDRE,

CONTIS,

BERARD

2024

Sci Rep

View full text Add to dashboard Cite

Serum protein electrophoresis can sometimes reveal polyclonal hypergammaglobulinemia. This electrophoretic abnormality can be caused by a variety of conditions and can be difficult to investigate. We sought to investigate screening practices in patients with hypergammaglobulinemia in order to establish diagnostic guidance strategies. We selected all patients with polyclonal hypergammaglobulinemia greater than or equal to 20 g/L over one year to identify the etiologies causing a significant increase in gammaglobulins in the absence of a monoclonal abnormality. We then selected patients who presented with this abnormality for the first time, with no known etiology. Clinical, medication, biological and imaging data were collected. In our study population with polyclonal hypergammaglobulinemia ( n = 155), the main etiologies identified were infections (56%), autoimmune and autoinflammatory diseases (20%), liver diseases (18%) and hematological and non-hematological malignancies (6%). Once hypergammaglobulinemia was identified, the clinical examination provided diagnostic orientation but was not sufficient to make the diagnosis. The initial assessment must investigate the most common pathologies including analysis of liver function, viral status, the search for signs of intravascular haemolysis, inflammatory markers, and blood cell count. At the second time point (unless there were suggestive clinical signs at presentation), more specific biological and imaging analyses were required. Finally, we propose a diagnostic guideline for a current, rational and optimal medical practice to assist clinicians in the management of patients with hypergammaglobulinemia.

show abstract

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma

Qiu

Kang

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐DNA load in peripheral blood of all 26,527 patients with lymphoma, and the clinical characteristics and prognosis of 202 patients were retrospectively analysed, including 100 patients with positive EBV‐DNA and 102 randomly selected patients with negative EBV‐DNA. We found that the average rate of EBV‐DNA positivity in lymphomas was 0.376%, and EBV‐DNA‐positive patients presented higher risk with elevated lactate dehydrogenase (LDH) and β2‐MG level, B symptoms, secondary hemophagocytic syndrome and lower objective response rate compared to EBV‐DNA‐negative patients. Multivariate analysis revealed EBV‐DNA‐positive patients had inferior progression‐free survival (PFS) and overall survival (OS) and EBV‐DNA level before treatment was related to PFS but not OS of T/NK cell lymphoma. In T/NK cell lymphoma, EBV‐DNA converting negative after treatment was correlated with better PFS but not OS, and second‐line therapy could induce more EBV‐DNA‐negative conversion compared to CHOP‐based therapy. In all, EBV‐DNA positivity before treatment can be a biomarker representing the tumour burden and an independent prognostic factor. EBV‐DNA‐negative conversion after treatment is a good prognostic factor for T/NK cell lymphomas.

show abstract

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma

Cited by 5 publications

References 23 publications

Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma

Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma

Etiological study of polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients and proposal of a diagnostic aid algorithm

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma

Contact Info

Product

Resources

About